Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Post by lscfaon Dec 19, 2023 12:30pm
167 Views
Post# 35791949

Conf call

Conf call

 

 

GLP-1 drugs have had no impact on sleep sales

 

Resmed also says no impact

 

Over 20 million Americans with sleep apnea have not been diagnosed yet

 

3% increase to reimbursement rates beginning Jan 01/24

 

< 5% of prescriptions from e-prescribing, room for efficiencies

 

Avg resupply patient spends $600/yr and increasing

 

Run rate on resupply orders $100 million/yr (169,000 patients)

 

Avg. resupply patient duration is 4 to 5 yrs.

 

Resupply biz ~ 40-50% of respiratory revenues

 

Resupply gross margins ~42%

 

Resupply is low touch biz, orders by email or app

 

Resupply ebitda > rental biz

 

Q4 organic growth 3.5%, above 8-10% annual target

 

At 90 sales people real time, up from 72 last Conf call

 

Sales people need 2 to 3 qtrs to ramp up

 

negotiations ongoing for additional insurance contracts

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

<< Previous
Bullboard Posts
Next >>